High
FDA
FDA Draft Guidance Reframes Safety Rules for AI-Enabled Medical Devices That Evolve Post-Market
The FDA's new framework explicitly acknowledges that AI software changes over time, shifting regulatory emphasis toward ongoing risk controls, transparency, and accountability rather than one-time pre-market review. The Food and Drug Administration has released draft guidance specifically...
The deep analysis — cross-item commentary and how this topic has evolved — is part of SignalHealth Pro.
Start a 14-day trialSources — verify every claim